N@N

Market Maker Surveillance Report. LJPC, NAII, AEGR, GLMD, IDRA, TBRA, Winning Stocks With Lowest Price Friction For Tuesday, S

^{Published on 2016-09-20 18:45:22 - WOPRAI}
 

September 20, 2016 / M2 PRESSWIRE / BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Tuesday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Tuesday there were 5710 companies with "abnormal" market making, 2652 companies with positive Friction Factors and 3111 companies with negative Friction Factors. Here is a list of the top companies with the largest percentage gain per share Tuesday and low price friction (bullish). This means that there was more buying than selling in the stocks and their stock prices rose faster with less Friction. La Jolla Pharmaceutical Company (NASDAQ:LJPC), Natural Alternatives International Inc (NASDAQ:NAII), Aegerion Pharmaceuticals Inc. (NASDAQ:AEGR), Galmed Pharmaceuticals (NASDAQ:GLMD), Idera Pharmaceuticals Inc. (NASDAQ:IDRA), Tobira Therapeutics Inc. (NASDAQ:TBRA). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .

Market Maker Friction Factor is shown in the chart below:

  Symbol  Change    Percent   Buy Volume   Buy %%    Sell Volume  Sell %%   Net Volume   Friction
  LJPC    $4.140    0.18%     142,052      39.20%    126,452      34.89%    15,600       38      
  NAII    $1.830    0.18%     143,631      36.52%    137,972      35.08%    5,659        31      
  AEGR    $0.600    0.32%     952,466      40.98%    687,891      29.60%    264,575      4,410   
  GLMD    $1.220    0.33%     304,816      35.33%    243,183      28.19%    61,633       505     
  IDRA    $0.490    0.21%     2,131,454    45.60%    1,771,783    37.90%    359,671      7,340   
  TBRA    $34.510   7.28%     4,413,016    34.58%    3,956,519    31.00%    456,497      132     

For example, the chart above shows LJPC with a dollar gain Tuesday of $4.14000 and a Friction Factor of 38 shares. That means that it only took 38 more shares of buying than selling to move LJPC higher by one penny. The Market Makers are currently allowing the stock to rise quickly (low friction). The combination of low friction and positive market direction can drive prices higher much faster than normal.

La Jolla Pharmaceutical Company (NASDAQ:LJPC) - La Jolla Pharmaceutical Company, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for life-threatening diseases. It engages in developing LJPC-501, a formulation of angiotensin II for the potential treatment of catecholamine-resistant hypotension and hepatorenal syndrome; and LJPC-401, a formulation of hepcidin for the treatment of conditions characterized by iron overload, such as hereditary hemochromatosis, beta thalassemia, sickle cell disease, and myelodysplastic syndrome. The company is also developing LJPC-30Sa and LJPC-30Sb, which are the gentamicin derivatives for the potential treatment of serious bacterial infections and rare genetic disorders, such as cystic fibrosis and Duchenne muscular dystrophy. La Jolla Pharmaceutical Company was founded in 1989 and is headquartered in San Diego, California..

Natural Alternatives International Inc (NASDAQ:NAII) - Natural Alternatives International, Inc. engages in formulating, manufacturing, and marketing nutritional supplements in the United States and internationally. The company offers private-label contract manufacturing services to companies that market and distribute vitamins, minerals, herbs, and other nutritional supplements, as well as other health care products. It also provides strategic partnering services, such as customized product formulation, clinical studies, manufacturing, marketing management and support, international regulatory and label law compliance, international product registration assistance, scientific research, proprietary ingredients, customer-specific nutritional product formulation, product testing and evaluation, packaging and delivery system design, regulatory review, and packaging in various formats and labeling designs. In addition, the company sells beta-alanine ingredient under the CarnoSyn trade name. It manufactures products in a various forms, including capsules, tablets, chewable wafers, and powders. Natural Alternatives International, Inc. was founded in 1980 and is headquartered in San Marcos, California..

Aegerion Pharmaceuticals Inc. (NASDAQ:AEGR) - APOLLO EYE GROUP INC.

Galmed Pharmaceuticals (NASDAQ:GLMD) - GOLD MEDAL RES LTD.

Idera Pharmaceuticals Inc. (NASDAQ:IDRA) - Idera Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for oncology and rare diseases in the United States. It uses two proprietary drug discovery technology platforms to design and develop drug candidates, including toll-like receptor targeting technology and third-generation antisense (3GA) technology. The company s lead drug candidate is IMO-8400, which is in Phase I/II clinical trials for the treatment of Waldenstr m s Macroglobulinemia and diffuse large B-cell lymphoma, as well as in Phase II clinical trial for the treatment of dermatomyositis. Its drug candidates also comprise IMO-9200, a drug candidate in Phase I clinical trial for use in selected autoimmune disease indications; and IMO-2055/IMO-2125 that are in Phase I/II clinical trials for applications as immune therapies for the treatment of cancer. In addition, the company is developing drug candidates to turn off the messenger RNA associated with disease causing genes. It has license and research collaboration agreement with Merck & Co. to research, develop, and commercialize vaccine products containing TLR7, TLR8, and TLR9 agonists in the fields of cancer, infectious diseases, and Alzheimer s disease; an agreement with Abbott Molecular Inc. for the development of an in vitro companion diagnostic test; a collaboration and license agreement with GSK to research, develop, and commercialize selected molecules from its 3GA technology for the treatment of selected targets in renal disease. Idera Pharmaceuticals, Inc. was founded in 1989 and is based in Cambridge, Massachusetts..

Tobira Therapeutics Inc. (NASDAQ:TBRA) - .

About BUYINS.NET

BUYINS.NET, http://www.buyins.net, monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market-maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:

REGULATORY & COMPLIANCE NEWS Friction Factor - Market maker surveillance system tracking Level II market makers in all stocks to determine Price Friction and compliance with new "Fair Market Making Requirements" Naked Shorts (RegSho) - Tracks EVERY failure to deliver in all US stocks and tracks all Threshold Security Lists daily for which stocks have naked shorts that are not in compliance with Regulation SHO

INVESTMENTS & TRADING Earnings - Predicts probability, price move and length of move before and after all US stock earnings reports Seasonality - Predicts probability, price move and length of move based on exact time of year for all US stocks Group Correlation - Tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups SqueezeTrigger - Massive database that tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock. Valuation - Tracks all known valuation models and applies them. GATS - Tracks and quantifies known trading strategies by backtesting, optimizing and running genetic algorithms and neural networks to ascertain best trading strategies. PatternScan - Automates tracking of every technical pattern and predicts next move in stocks. Insider - Tracks insiders trading records and determines trading performance. Trades by higher-level insiders are generally more predictive than trades by lower level insiders Events - Tracks patterns directly correlated to specific events.

SqueezeTrigger is a registered trademark, Reg. No. 3,120,641

DISCLAIMER:

BUYINS.NET is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. [symbol] has not approved the statements made in this release. Please read our report and visit our web site, http://www.buyins.net, for complete risks and disclosures.

Contact: BUYINS.NET Thomas Ronk 800-715-9999 tom@buyins.net http://www.buyins.net